#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hepato-lenticular degeneration Cystic fibrosis lung Neuroblastoma recurrent Drug eruption Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome Myotonic dystrophy Inflammatory myofibroblastic tumour Progressive multifocal leukoencephalopathy Mantle cell lymphoma stage II Leukodystrophy Lupus nephritis Scleroderma associated digital ulcer Cardiac failure acute Essential thrombocythaemia Corneal neovascularisation More trials…

    Learn about Rare Diseases

    Phenylketonuria – Treatment Primary mediastinal large B-cell lymphoma – Diagnostics Pelizaeus-Merzbacher disease – Diagnostics Glomerulonephritis membranous – Diagnostics Hypereosinophilic syndrome – Life with Disease Myxofibrosarcoma – Treatment Leiomyosarcoma – Diagnostics IgA nephropathy – Basic Information Rosai-Dorfman syndrome – Basic Information Myelodysplastic syndrome with excess blasts – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Alectinib Ly3819469 Sodium COLESEVELAM HYDROCHLORIDE Zanidatamab R-Azasetron Besilate Palbociclib Ketotifen Hydrogen Fumarate Human Coagulation Factor Ii Bulevirtide Aluminium Oxide, Hydrated Digitoxin Ocrelizumab 7-Ethyl-10-Hydroxycamptothecin THEOPHYLLINE ANHYDROUS Ht-29-B Nacystelyn Diphenhydramine Hydrochloride Glycopyrronium Bromide Anselamimab Divarasib More therapies…

    Learn about Your Condition

    Fungal infection Hydrocephalus Immunodeficiency Nephropathy Short-bowel syndrome Chronic spontaneous urticaria Leiomyosarcoma metastatic Facial paresis Milk allergy B-cell lymphoma recurrent Pseudomonas infection Cardiac valve disease Lung adenocarcinoma Renal cancer Ependymoma malignant More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Cystic fibrosis

  • Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor in Children and Adults with Cystic Fibrosis Aged 2 Years and Older

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Cystic fibrosis
    Investigated Drugs:
    • Elexacaftor
    • Ivacaftor
    • Tezacaftor
    Germany

  • Study on Thymalfasin for Adults with Cystic Fibrosis

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cystic fibrosis
    Investigated Drugs:
    • Thymalfasin
    Italy

  • Study on the Safety and Tolerability of Elexacaftor, Tezacaftor, and Ivacaftor in Children with Cystic Fibrosis Aged 12 to Less Than 24 Months

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Cystic fibrosis
    Investigated Drugs:
    • Elexacaftor
    • Ivacaftor
    • Tezacaftor
    Denmark Germany The Netherlands

  • Study of anakinra safety and effectiveness given by injection under the skin in patients with cystic fibrosis

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Anakinra
    Germany

  • Study on the Effects of Dirocaftor, Posenacaftor, and Nesolicaftor for Adults with Cystic Fibrosis

    Not recruiting

    2 1
    Investigated Diseases:
    • Cystic fibrosis
    Investigated Drugs:
    • Dirocaftor
    • Nesolicaftor
    • Posenacaftor
    Belgium Czechia France Germany Italy The Netherlands +3

  • Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Deutivacaftor
    • Vanzacaftor
    • Tezacaftor
    Austria Belgium Czechia Denmark France Germany +10
Previous Page
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!